$The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia$

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia

Abstract: The antiapoptotic protein myeloid cell leukemia 1 (Mcl-1) promotes cell survival in acute myeloid leukemia (AML), and its overexpression is associated with resistance to venetoclax. Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, indirectly decreases Mcl-1 protein expression and h...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yesid Alvarado-Valero, Rachel J. Cook, Shira N. Dinner, Michael Keng, Kebede H. Begna, Nathalie Javidi-Sharifi, Sameem Abedin, Monzr M. Al Malki, Vijaya Raj Bhatt, Prabhu Rajagopalan, Min Tang, Sandra E. Wiley, Richard G. Ghalie, Matthew S. Davids
Format:	Article
Language:	English
Published:	Elsevier 2025-08-01
Series:	Blood Neoplasia
Online Access:	http://www.sciencedirect.com/science/article/pii/S2950328025000433
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia
by: Lixiazi He, et al.
Published: (2022-03-01)

Venetoclax – The game-changer in hematology
by: Tanmoy Kumar Mandal, et al.
Published: (2020-01-01)

Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy
by: Rafael Madero‐Marroquin, et al.
Published: (2025-06-01)

Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy
by: Isla M. Johnson, et al.
Published: (2025-02-01)

Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
by: Mahesh Tambe, et al.
Published: (2024-10-01)

Venetoclax Plus CyBorD Induction Therapy and Venetoclax Maintenance Treatment for Immunoglobulin Light Chain Amyloidosis with t(11;14) Translocation
by: Gréta Garami, et al.
Published: (2025-01-01)

VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (literature review)
by: T. E. Byalik
Published: (2018-07-01)

(R)-WAC-224, a new anticancer quinolone, combined with venetoclax and azacitidine overcomes venetoclax-resistant AML through MCL-1 downregulation
by: Hiroshi Ureshino, et al.
Published: (2025-05-01)

Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN
by: Naveen Pemmaraju, et al.
Published: (2025-05-01)

Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
by: Renshi Kawakatsu, et al.
Published: (2024-02-01)

Enhancing venetoclax efficacy in leukemia through association with HDAC inhibitors
by: Jorge Antonio Elias Godoy Carlos, et al.
Published: (2025-04-01)

Targeting CDK2 for cancer therapy
by: Erik S. Knudsen, et al.
Published: (2025-08-01)

Correction: Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
by: Renshi Kawakatsu, et al.
Published: (2025-07-01)

Successful experience of venetoclax in the treatment of refractory primary plasma cell leukemia
by: I. V. Cherkashina, et al.
Published: (2025-03-01)

TREATMENT OF BLAST PHASE MYELOPROLIFERATIVE NEOPLASM WITH THE COMBINATION OF AZACITIDINE, VENETOCLAX AND RUXOLITINIB
by: Fidan Khalilova, et al.
Published: (2025-07-01)

Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia
by: Yu Cui, et al.
Published: (2024-12-01)

Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients
by: Paul J. Hengeveld, et al.
Published: (2025-01-01)

Valproic Acid Enhances Venetoclax Efficacy in Targeting Acute Myeloid Leukemia
by: Renshi Kawakatsu, et al.
Published: (2025-01-01)

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML
by: Petra Bašová, et al.
Published: (2025-01-01)

Identification of new inhibitors of the kinase activity of CDK2 and CDK9 by molecular modeling and high-efficiency screening
by: G.V. Andrianov, et al.
Published: (2021-12-01)

Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine–venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net
by: Minoru Kanaya, et al.
Published: (2025-07-01)

Targeting CDK4/6 in breast cancer
by: Anusha Shanabag, et al.
Published: (2025-02-01)

CDK14 regulates the development and repair of lung
by: Jian-wei Chen, et al.
Published: (2025-01-01)

Targeting CDK9 for treatment of colorectal cancer
by: Muhammed H. Rahaman, et al.
Published: (2019-10-01)

Prognostic significance of monocytic-like phenotype in patients with AML treated with venetoclax and azacytidine
by: Lin-Pierre Zhao, et al.
Published: (2025-07-01)

Therapeutic Potential of Venetoclax and Selinexor in Targeting Hypoxia‐Induced Vulnerabilities in Multiple Myeloma
by: Seiichi Okabe, et al.
Published: (2025-06-01)

Venetoclax confers synthetic lethality to chidamide in preclinical models with transformed follicular lymphoma
by: Mengya Zhong, et al.
Published: (2025-05-01)

Effective treatment of peritoneal myeloid sarcoma with decitabine and venetoclax: A case report
by: Kavya Sudireddy, et al.
Published: (2025-01-01)

A Population Pharmacokinetics Study of Venetoclax Concomitant with Voriconazole in Patients with Hematologic Malignancies
by: Yang J, et al.
Published: (2025-05-01)

Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia
by: Fiona C. Brown, et al.
Published: (2025-01-01)

Case Report: Decitabine and venetoclax sequentially followed by FLAG-Ida and venetoclax with immediate allogeneic stem cell transplantation in newly diagnosed acute myeloid leukemia with chromosome 3 inversion/MECOM rearrangement
by: Andrius Žučenka, et al.
Published: (2025-03-01)

Preparation for mitosis requires gradual CDK1 activation
by: Karen Akopyan, et al.
Published: (2025-05-01)

Tankyrase inhibition sensitizes cells to CDK4 blockade.
by: Miguel Foronda, et al.
Published: (2019-01-01)

In silico identification of novel CDK4 inhibitors for retinoblastoma
by: Mukesh kumar, et al.
Published: (2024-12-01)

Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia
by: Kendall Diebold, et al.
Published: (2025-06-01)

Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies
by: Binu Kandathilparambil Sasi, et al.
Published: (2025-06-01)

Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days
by: Naseema Gangat, et al.
Published: (2025-04-01)

Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia
by: Elżbieta Iskierka-Jażdżewska, et al.
Published: (2025-01-01)

Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents
by: Dian Jin, et al.
Published: (2024-07-01)

Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS)
by: Heather Klocke, et al.
Published: (2020-01-01)